Long –term safety of omalizumab in patients with severe asthma
Omalizumab is a recombinant humanized monoclonal anti-immunoglobulin E (IgE) antibody that inhibits the binding of IgE to high-affinity receptors for allergic uncontrolled severe asthma. The primary objective of this study is to evaluate the long-term safety of Omalizumab in a real-world setting.
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Maria Paixao, Itziar Eusebio, Maria G ómez Viciana, Cristina Juárez, Rocio Díaz-Campos, Consuelo Fernandez, Ismael G-Moguel, Jesus Crespo Source Type: research